secukinumab
Trade name: cosentyx
mAbapproved
Approved
Jan 21, 2015
Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It binds to the protein interleukin (IL)-17A and is marketed by Novartis. — Wikipedia
Clinical trial activity
202 trials · 108 clinical orgs · 1 marketing orgs
Phase 1
27
Phase 2
146
Phase 3
98
Phase 4
33
Earliest trial started Dec 1, 2005 (NCT00669942)
Timeline
Indications
Studied for
- Alopecia Areata · Phase 2
- Arthritis · Phase 3
- Arthritis, Juvenile · Phase 3
- Arthritis, Psoriatic · Phase 4
- Arthritis, Rheumatoid · Phase 4
- Asthma · Phase 2
- Autoimmune Diseases · Phase 2
- Axial Spondyloarthritis · Phase 4
- Behcet Syndrome · Phase 3
- Biopsy · Phase 4
- Carcinoma, Giant Cell · Phase 3
- Colorectal Neoplasms · Phase 1/Phase 2
- COVID-19 · Phase 2
- Crohn Disease · Phase 2
- Dermatitis, Allergic Contact · Phase 3
- Dermatitis, Atopic · Phase 2
- Diabetes Mellitus, Type 1 · Phase 2
- Drug Therapy · Phase 4
- Dry Eye Syndromes · Phase 2
- Giant Cell Arteritis · Phase 3
- Graves Ophthalmopathy · Phase 3
- Healthy Volunteers · Phase 4
- Hidradenitis Suppurativa · Phase 3
- Hyperkeratosis, Epidermolytic · Phase 2
- Ichthyosiform Erythroderma, Congenital · Phase 2
- Ichthyosis · Phase 4
- Ichthyosis, Lamellar · Phase 2
- Inflammation · Phase 4
- Inflammatory Bowel Diseases · Phase 2
- Lichen Planus · Phase 2
- Lupus Erythematosus, Discoid · Phase 2
- Lupus Nephritis · Phase 3
- Melanoma · Phase 1
- Metabolic Syndrome · Phase 4
- Multiple Sclerosis · Phase 2
- Multiple Sclerosis, Relapsing-Remitting · Phase 2
- Necrobiosis Lipoidica · Phase 2
- Netherton Syndrome · Phase 2
- Non-alcoholic Fatty Liver Disease · Phase 3
- Non-Radiographic Axial Spondyloarthritis · Phase 4
- Pharmacokinetics · Phase 1
- Pityriasis Rubra Pilaris · Phase 1
- Polymyalgia Rheumatica · Phase 3
- Premature Ejaculation · Phase 1
- Pyoderma Gangrenosum · Phase 2
- Rheumatic Diseases · Phase 2
- Rosacea · Phase 1/Phase 2
- Spondylarthritis · Phase 4
- Spondylarthropathies · Phase 3
- Spondylitis · Phase 3
- Spondylitis, Ankylosing · Phase 4
- Substance Withdrawal Syndrome · Phase 3
- Tendinopathy · Phase 3
- Uveitis · Phase 3
- Vitiligo · Phase 4
Mechanism of action
- Interleukin 17AINHIBITOR
IL17A inhibitor
Approval history
- approvedJan 21, 2015
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
First in class
Sources
- WikipediaSecukinumab ↗
- NCATSDLG4EML025 ↗
- ChEMBLCHEMBL1743068 ↗
Also known as
- ain457
- ain457
- ain457
- ain 457
- ain-457
- ain-457
- ain-457
- cosentyx
- cosentyx
- cosentyx
- secukinumab
- secukinumab
- secukinumab
- secukinumab
- secukinumab
- secukinumab
- secukinumab
- secukinumab
- secukinumab
- secukinumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07237594 | Phase 1 | Jan 1, 2026 | Duke University |
| NCT07254325 | Phase 1 | Dec 15, 2025 | Taizhou Mabtech Pharmaceutical Co., Ltd. |
| NCT07261072 | Phase 4 | Dec 1, 2025 | — |
| NCT07138898 | Phase 2 | Sep 30, 2025 | New York University |
| NCT06945107 | Phase 3 | May 27, 2025 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT06630559 | Phase 3 | Apr 30, 2025 | Celltrion |
| NCT06751238 | Phase 1 | Apr 15, 2025 | Novartis |
| NCT06833112 | Phase 4 | Feb 28, 2025 | Guizhou Medical University |
| NCT06811558 | N/A | Feb 1, 2025 | Zhejiang University |
| NCT06707246 | N/A | Dec 15, 2024 | Jinhua Central Hospital, Nanchang University, Ningbo No. 1 Hospital, The First People's Hospital of Huzhou, Wenzhou Medical University, Zhejiang University |
| NCT06398106 | Phase 4 | Sep 1, 2024 | Ghent University, Katholieke Universiteit Leuven |
| NCT06398652 | Phase 3 | Aug 27, 2024 | Fudan University, Taizhou Mabtech Pharmaceutical Co., Ltd. |
| NCT06331312 | Phase 3 | Jun 28, 2024 | Novartis |
| NCT06130540 | Phase 1 | Mar 15, 2024 | Novartis |
| NCT07054970 | Phase 1 | Jan 12, 2024 | Celltrion, Kitasato University |
| NCT06126718 | Phase 1 | Nov 30, 2023 | Qingdao University, Shanghai Bioray Laboratory Inc. |
| NCT05975268 | Phase 3 | Aug 28, 2023 | Shanghai Junshi Bioscience Co.,Ltd. |
| NCT06110676 | Phase 3 | Aug 21, 2023 | Livzon Pharmaceutical Group Inc. |
| NCT05722522 | Phase 3 | Aug 10, 2023 | Novartis |
| NCT05758415 | Phase 3 | Aug 2, 2023 | Novartis |
Showing 20 of 202 trials
Page 1 / 11
Organizations
Research & Development (108)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 150 | 132 | 5 | 2005 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 4 | 3 | 2 | 2015 |
| Ghent University | Academic/Hospital | 3 | 2 | 1 | 2016 |
| Shanghai Junshi Bioscience Co.,Ltd. | For profit | 3 | 3 | 3 | 2020 |
| Taizhou Mabtech Pharmaceutical Co., Ltd. | For profit | 3 | 3 | 2 | 2023 |
| University of Erlangen-Nuremberg | Academic/Hospital | 3 | 3 | 3 | 2015 |
| University of Pennsylvania | Academic/Hospital | 3 | 1 | 1 | 2016 |
| Zhejiang University | Academic/Hospital | 3 | 3 | 1 | 2023 |
| AbbVie | For profit | 2 | 1 | 2 | 2018 |
| Biothera | For profit | 2 | 2 | 2 | 2021 |
| Celltrion | For profit | 2 | 2 | 2 | 2024 |
| Eli Lilly | For profit | 2 | 1 | 2 | 2018 |
| Harvard University | Academic/Hospital | 2 | 2 | 1 | 2019 |
| Katholieke Universiteit Leuven | Academic/Hospital | 2 | 0 | 1 | 2020 |
| Plethora Solutions Ltd | For profit | 2 | 2 | 1 | 2009 |
| Shionogi | For profit | 2 | 0 | 1 | 2009 |
| University of Copenhagen | Academic/Hospital | 2 | 2 | 2 | 2016 |
| AIDS Malignancy Consortium | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Aix-University of Marseille | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Akdeniz University | Academic/Hospital | 1 | 0 | 1 | 2016 |
108 organizations
Page 1 / 6